FDA approves Dr. Reddy’s generic anticoagulant drug
HYDERABAD, India — The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.
Dr. Reddy’s and Brisbane, Australia-based Alchemia announced the FDA approval of fondaparinux sodium injection in the 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL strengths. Alchemia owns the patents covering the process for synthesis of fondaparinux.
The drug is a generic version of GlaxoSmithKline’s Arixtra. Arixtra had sales of about $340 million during the 12-month period ended in May, according to IMS Health.
Teva completes acquisition of Japanese generics company
JERUSALEM — Teva Pharmaceutical Industries has completed its acquisition of Japan’s third-largest generics company, Teva said.
The Israeli drug maker, the world’s largest maker of generic drugs, announced that it had acquired effectively all the outstanding shares of Taiyo Pharmaceutical Industry Co. for $934 million.
“This is an important milestone in executing Teva’s long-term strategic plan,” Teva president and CEO Shlomo Yanai said in a statement. “The acquisitio of Taiyo, along with Teva’s existing Japanese business, assures that Teva will deliver on our strategic objective of becoming a leading player in Japan.”
Taiyo had sales of about $530 million in 2010, and its acquisition adds more than 550 products to Teva’s portfolio, as well as Taiyo’s research and development team, local regulatory expertise and a factory. Teva said it expected its sales in Japan to reach $1 billion after the purchase.
Valeant Pharmaceuticals purchases Johnson & Johnson dermatology subsidiary
MISSISSAUGA, Ontario — Valeant Pharmaceuticals has purchased a dermatology subsidiary from Johnson & Johnson, the Canadian drug maker said Friday.
The $345 million acquisition of the Ortho Dermatologics division of J&J subsidiary Janssen Pharmaceuticals follows Valeant’s $425 million purchase of Dermik, the skin care business of French drug maker Sanofi. Ortho Dermatologics’ portfolio includes the drugs Retin-A Micro, Ertaczo and Renova, which collectively had sales of about $150 million in 2010.
“With the combination of this transaction and other recently announced transactions, Valeant is well on its way to being one of the leading companies in dermatology,” Valeant chairman and CEO J. Michael Pearson said in a statement. “We believe that dermatology remains an attractive therapeutic area for Valeant, and we are pleased to be able to add another strong franchise to our growing operations.”